Community-Acquired Bacterial Pneumonia Global Clinical Trials Review, H1, 2017

Community-Acquired Bacterial Pneumonia Global Clinical Trials Review, H1, 2017

Summary

GlobalDatas clinical trial report, Community-Acquired Bacterial Pneumonia Global Clinical Trials Review, H1, 2017" provides an overview of Community-Acquired Bacterial Pneumonia clinical trials scenario. This report provides top line data relating to the clinical trials on Community-Acquired Bacterial Pneumonia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalDatas proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Report Guidance 6
GlobalData Clinical Trials Report Coverage 7
Clinical Trials by Region 8
Clinical Trials and Average Enrollment by Country 9
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 12
Top Five Countries Contributing to Clinical Trials in Europe 13
Top Countries Contributing to Clinical Trials in North America 14
Top Countries Contributing to Clinical Trials in Middle East and Africa 15
Top Five Countries Contributing to Clinical Trials in Central and South America 16
Clinical Trials by G7 Countries: Proportion of Community-Acquired Bacterial Pneumonia to Infectious Disease Clinical Trials 17
Clinical Trials by Phase in G7 Countries 19
Clinical Trials in G7 Countries by Trial Status 20
Clinical Trials by E7 Countries: Proportion of Community-Acquired Bacterial Pneumonia to Infectious Disease Clinical Trials 21
Clinical Trials by Phase in E7 Countries 23
Clinical Trials in E7 Countries by Trial Status 24
Clinical Trials by Phase 25
In Progress Trials by Phase 26
Clinical Trials by Trial Status 27
Clinical Trials by End Point Status 29
Subjects Recruited Over a Period of Time 30
Clinical Trials by Sponsor Type 31
Prominent Sponsors 32
Top Companies Participating in Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials 34
Prominent Drugs 36
Latest Clinical Trials News on Community-Acquired Bacterial Pneumonia 38
Jun 05, 2017: Nabriva Therapeutics Announces Webcast of Analyst & Investor Day on June 19, 2017 38
Jun 02, 2017: Nabriva Therapeutics to present data at ASM Microbe supporting ongoing Phase 3 clinical development program for lefamulin 38
Jun 02, 2017: Eight Presentations at ASM Microbe Include Late Breaker From Cempras Phase 3 Fusidic Acid Study and Solithromycin Data on Gonorrhea and Otitis Media 38
Apr 25, 2017: Omadacycline Concentrations Exceed Tigecycline Levels in Lungs and Epithelial Lining Fluid According to Pharmacokinetic/Pharmacodynamic Data 39
Apr 21, 2017: Cempra Presents Data at ECCMID Highlighting Need for New CABP Therapies and Activity of Solithromycin in Key Population Groups 40
Apr 13, 2017: Nabriva Therapeutics to present data at ECCMID supporting ongoing Phase 3 clinical development program for lefamulin 40
Apr 11, 2017: Nabriva Therapeutics Announces Enrollment Completion for LEAP 1, a Phase 3 Clinical Trial Evaluating Lefamulin in Community-Acquired Bacterial Pneumonia 41
Clinical Trial Profile Snapshots 42
Appendix 94
Abbreviations 94
Definitions 94
Research Methodology 95
Secondary Research 95
About GlobalData 96
Contact Us 96
Source 96

List Of Tables

Community-Acquired Bacterial Pneumonia Therapeutics, Global, Clinical Trials by Region, 2017* 8
Community-Acquired Bacterial Pneumonia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 10
Community-Acquired Bacterial Pneumonia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 11
Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017* 12
Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 13
Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, North America, Top Countries, 2017* 14
Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2017* 15
Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2017* 16
Proportion of Community-Acquired Bacterial Pneumonia to Infectious Disease Clinical Trials, G7 Countries (%), 2017* 18
Community-Acquired Bacterial Pneumonia Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 19
Community-Acquired Bacterial Pneumonia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 20
Proportion of Community-Acquired Bacterial Pneumonia to Infectious Disease Clinical Trials, E7 Countries (%), 2017* 22
Community-Acquired Bacterial Pneumonia Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 23
Community-Acquired Bacterial Pneumonia Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 24
Community-Acquired Bacterial Pneumonia Therapeutics, Global, Clinical Trials by Phase, 2017* 25
Community-Acquired Bacterial Pneumonia Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 26
Community-Acquired Bacterial Pneumonia Therapeutics, Global, Clinical Trials by Trial Status, 2017* 28
Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, Global, by End Point Status, 2017* 29
Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 30
Community-Acquired Bacterial Pneumonia Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 31
Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 33
Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 35
Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 37

List Of Figures

Community-Acquired Bacterial Pneumonia Therapeutics, Global, Clinical Trials by Region (%), 2017* 8
Community-Acquired Bacterial Pneumonia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 9
Community-Acquired Bacterial Pneumonia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 11
Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017* 12
Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017* 13
Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, North America, Top Countries (%), 2017* 14
Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2017* 15
Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2017* 16
Proportion of Community-Acquired Bacterial Pneumonia to Infectious Disease Clinical Trials, G7 Countries (%), 2017* 17
Community-Acquired Bacterial Pneumonia Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 19
Community-Acquired Bacterial Pneumonia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 20
Proportion of Community-Acquired Bacterial Pneumonia to Infectious Disease Clinical Trials, E7 Countries (%), 2017* 21
Community-Acquired Bacterial Pneumonia Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 23
Community-Acquired Bacterial Pneumonia Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 24
Community-Acquired Bacterial Pneumonia Therapeutics, Global, Clinical Trials by Phase (%), 2017* 25
Community-Acquired Bacterial Pneumonia Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* 26
Community-Acquired Bacterial Pneumonia Therapeutics, Global, Clinical Trials by Trial Status, 2017* 27
Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, Global, by End Point Status, 2017* 29
Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 30
Community-Acquired Bacterial Pneumonia Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 31
Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 32
Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 34
Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 36
GlobalData Methodology 95

Fill The Form For Sample Request

Full Name*

Business Email *

E-mail

Country *

Select Country Albania Algeria Afghanistan Angola Argentina Armenia Aruba Australia Austria Azerbaijan Andorra Anguilla Bahrain Bangladesh Barbados Belarus Belgium Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Brazil Brunei Bulgaria Burkina Faso Burundi Bosnia Cambodia Cameroon Central African Republic Chad Chile China Colombia Comoros Congo (Brazzaville) Cook Islands Costa Rica Cote d Ivoire Croatia Cuba Cyprus Czech Republic Cayman Islands Denmark Djibouti Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Fiji Finland France Gabon Gambia Georgia Germany Ghana Gibraltar Greece Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Honduras Hong Kong Hungary Herzegovina Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kuwait Korea Kyrgyzstan Laos Latvia Lebanon Lesotho Liberia Libya Lithuania Luxembourg Liechtenstein Macau Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Mauritania Mauritius Mexico Moldova Monaco Mongolia Montenegro Morocco Mozambique Myanmar Middle East & North Africa (MENA) Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria North Korea Norway Oman Pakistan Palau Palestinian Territories Panama Papua New Guinea Paraguay Peru Philippines Poland Portugal Puerto Rico Palestine Qatar Romania Russia Rwanda Samoa Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Korea Spain Sri Lanka Saint Kitts and Nevis Saint Vincent and the Grenadines Sudan Suriname Swaziland Sweden Switzerland Syria Scotland San Marino Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States of America Uruguay Uzbekistan Uraguay Vanuatu Venezuela Vietnam Virgin Islands Yemen Zambia Zimbabwe Canada Grenada Cape Verde Belize Curacao Republic of Srpska Antigua and Barbuda Saint Lucia Falkland Islands Faroe Islands Federated States of Micronesia Guadeloupe Martinique Montserrat Niue

Contact No *

Alternate No

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available